ROLE OF RESVERATROL IN THE TREATMENT OF PATIENTS WITH SEVERE PREECLAMPSIA

Document Type : Preliminary preprint short reports of original research

Authors

1 Obstetrics and Gynecology Department, Faculty of Medicine, Alexandria University, Egypt

2 Obstetrics and Gynaecology department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

3 Obstetric and Gynecology department, faculty of Medicine, Alexandria University, Alexandria

4 Department of Obstetrics & Gynaecology, Faculty of Medicine, Alexandria University

Abstract

Preeclampsia is a multisystem progressive disorder characterized by the new onset of hypertension and proteinuria or the new onset of hypertension plus significant end-organ dysfunction with or without proteinuria, typically presenting after 20 weeks of gestation or postpartum. Incidence: About 4.6 % of pregnancies worldwide are complicated by preeclampsia. Variations in incidence reflect differences in the maternal age distribution and proportion of nulliparous patients in the population. The incidence is increasing, likely related to population-level increases in risk factors for the disease. According to severity, preeclampsia is classified into non severe and severe. Labetalol is a selective alpha blocker and a nonselective beta blocker that produces vasodilatation and results in a decrease in systemic vascular resistance. Resveratrol 3,5,40-trihydroxy-trans-stilbene an antioxidant polyphenolic compound found in various plants and foods including grapes. Resveratrol can induce uterine arteries relaxation during PE pathological events.
Aim of the work:
The present study was designed to evaluate the effect of adding Resveratrol to labetalol in the treatment of severe preeclampsia through assessment of changes in blood pressure and the time needed for adequate control of blood pressure before termination of pregnancy.

Keywords

ALEXMED ePosters
Volume 6, Issue 1
January 2024
Pages 49-50

Files

Share

How to cite

Statistics